Benzene bestildastine tablets, pharmacy price reduction 90%! Only 7.5 yuan per box

The fifth batch of collected drugs landed, involving designated pharmacies, benzene belatedestin tablets selected price of 7.5 yuan, the market price of 50 yuan, a sharp drop of 90%.

Benzene bethestine tablets 7.5 yuan, the price dropped by 90%

According to the information of Wuhan Municipal Medical Insurance Bureau, since October 10, the results of the fifth batch of centralized procurement of drugs organized by the state (Hubei) have been implemented in Wuhan. In addition to the medical institutions that meet the requirements, the executive agencies also include medical insurance designated retail pharmacies.

It is reported that the national collection of drugs in Wuhan involves 61 varieties and 81 product specifications, and the average price of selected drugs is reduced by 56%, and the highest price reduction is 98.3%.

Take benzene bethestine tablets for example, the online platform market price of 50 yuan (10mg * 10 tablets / box, Tianjin Tianbian Pharmaceutical production), and the price of the selection of this collection is only 7.5 yuan (the same specifications, the same manufacturer), the price drop is close to 90%. If calculated according to the collection price, adult patients who take the drug for a total of 1 year can save about 3,000 yuan in expenses.

It is understood that benzene bestildastine tablets mainly treat allergic rhinitis, urticaria, itching caused by skin diseases (eczema, dermatitis, pruritus), which is a commonly used disease prescription drug. On December 25, 2020, the National Medical Insurance Bureau and the Ministry of Human Resources and Social Security jointly issued the "National Basic Medical Insurance, Work Injury Insurance and Maternity Insurance Drug Catalogue (2020)", and Betastine was listed as a Class B drug.

According to data from the intranet, in the terminal market of China's public medical institutions, Bethestine tablets showed a rapid growth trend, with sales of 44.95 million yuan in 2018, an increase of 26.92% year-on-year, and sales of 35.41 million yuan in 2017, an increase of more than 136% year-on-year.

According to the information of the State Food and Drug Administration, there are three main domestic manufacturers of benzene belatedestine tablets: Tianjin Tianbian Pharmaceutical Co., Ltd., Chongqing Huabang Pharmaceutical Co., Ltd., and Hangzhou Minsheng Pharmaceutical Co., Ltd.

Saxagliptin tablets 20.74 yuan, a 57% reduction in price

In addition to benzene belatacetin tablets, the decline in other drugs in the fifth batch of drug collection list is still not small.

For example, olopatadine tablets (5mg*12 tablets/box, produced by Jiangsu Wanqi Pharmaceutical Commissioned by Beijing Ailijia Pharmaceutical Technology), which also treat allergic rhinitis and urticaria, have a market sales price of 48 yuan and a collection price of 29.58 yuan, a decrease of 38%.

Saxagliptin tablets for type 2 diabetes mellitus (5mg*7 tablets*1 plate/box, produced by Chia Tai Tianqing Pharmaceutical), the market sales price is 48 yuan, and the selection price in the collection is 20.74 yuan, a decrease of 57%. It is worth mentioning that saxagliptin tablets are relatively new hypoglycemic drugs, which are not easy to cause hypoglycemia, have high safety, and are concerned by the elderly with cardiovascular and cerebrovascular diseases.

Long-term treatment of coronary heart disease isosorbide mononitrate extended-release tablets (40mg * 12 tablets * 2 plates / box, Qilu Pharmaceutical production), the market price of 61 yuan, the collection price of 23.03 yuan, a decrease of 62%.

Rivaroxaban tablets (10mg*12pcs*1 plate/box, jinhua Kang'enbei production), the market price is 128 yuan, and the price of the selection is 7.45 yuan, a decrease of 94%. It is understood that rivaroxaban tablets are used in adult patients with elective hip or knee replacement surgery to prevent venous thrombosis.

Pharmacies face challenges in entering the collection or not

In the latest national fifth batch of collection catalogues, the average reduction of selected drugs is 56%, and the highest reduction is 97%, covering the range of common chronic diseases and major diseases such as hypertension, coronary heart disease, diabetes, lung cancer, breast cancer, etc. In addition, the fifth batch of collection is also the largest collection of drugs organized by the state in history, involving the largest number of varieties and the highest procurement amount, of which the national procurement amount of public hospitals is 55 billion yuan.

As of the fifth round of national collection, a total of 218 varieties of drugs have been included in the national organization, and in accordance with the requirements of the "14th Five-Year Plan" For The National Medical Security Plan, the national and provincial centralized procurement varieties in various provinces (autonomous regions and municipalities directly under the Central Government) have reached more than 500 varieties. This means that by 2025, nearly 300 drugs will be included and usher in a major price reduction.

In addition, recently many provinces across the country issued a notice that the fifth batch of national group selection results began to be implemented in October, and some places clearly stated that medical insurance designated pharmacies were used as the implementation agency.

With the fifth batch of national drug collection in many provinces, it can be inferred that national implementation is a foregone conclusion, and the participation of pharmacies in collection has become a trend.

It is worth noting that after pharmacies enter the collection, it will further intensify the competition in the industry, and small and medium-sized pharmacies are often at a disadvantage compared with chain enterprises, and it is easy to give up the amount of quotation, and then lose the hand with the collection of drugs, and finally lose the flow of customers.

The relevant person in charge of Guangdong's three doctors once told Guangzhou Daily that in the third batch of centralized procurement of national drugs, more than 28,000 retail pharmacies in Guangdong participated in the report, accounting for 50% of the total number of pharmacies in Guangdong. According to past experience, due to production capacity problems, retail pharmacies that have not participated in the reporting volume will be difficult to obtain the collection varieties and will be at a disadvantage in the future competition.

Even if they obtain collected drugs, pharmacies will also face difficulties in their operations.

Some industry views believe that due to the very low price of collection and procurement, the profit margin given to pharmacies is also low, but according to the agreement, pharmacy enterprises participating in the collection and reporting volume must complete the procurement of the reported amount within one year, and the collection related categories will be mainly used as drainage commodities. Therefore, under the premise of digesting the purchase volume, how to balance the "drainage" and "profit" of collected drugs is a very worthy problem to consider.